Fewer eye shots? new study tests quarterly faricimab for wet AMD
NCT ID NCT06742307
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study looks at whether people with wet age-related macular degeneration (AMD) can maintain stable vision with faricimab injections only every 12-16 weeks, after an initial series of 2-4 loading doses. About 40 participants aged 50 and older with active disease will be followed for a year. The goal is to see if this less frequent schedule can prevent disease recurrence and reduce the burden of monthly eye injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION CHOROIDAL NEOVASCULARIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Ophthalmology, United Chrisitian Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.